Fabrice BARLESI
Gustave Roussy, Cancer Campus, Grand Paris · CHU Hopital Nord Marseille · IFCT, Aix Marseille Université / Assistance Publique Hôpitaux de Marseille
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Fabrice BARLESI as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 02:00 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05865730 · A Study of Oncobax®-AK in Patients With Advanced Solid TumorsEverImmune · unknown · Carcinoma, Renal Cell, Carcinoma, Non-Small-Cell Lung · principal investigator
- Ph3NCT05221840 · A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung CancerAstraZeneca · active not recruiting · Non-Small Cell Lung Cancer · principal investigator
- Ph2NCT02117167 · SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC PatientsUNICANCER · completed · Non-small Cell Lung Cancer Metastatic · principal investigator
- N/ANCT01700582 · French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular TestingsIntergroupe Francophone de Cancerologie Thoracique · completed · Carcinoma, Non-Small-Cell Lung, ALK Gene Mutation, KRAS Gene Mutation · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 02:00 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 02:00 UTC. The ranking covers the 200 most relevant of 128 PubMed records, and a shared surname and initials can bring in a namesake. All 128 on PubMed
- 7,991 citationsRCR 252.7
- 4,018 citationsRCR 132.8
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.N Engl J Med · 20183,177 citationsRCR 109.0
- Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.N Engl J Med · 20192,327 citationsRCR 84.6
- Sotorasib for Lung Cancers with KRAS p.G12C Mutation.N Engl J Med · 20211,561 citationsRCR 84.2
- KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.N Engl J Med · 20201,444 citationsRCR 58.9
- 835 citationsRCR 20.0
- Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.Lancet Respir Med · 2019824 citationsRCR 28.8
- 732 citationsRCR 21.9
- Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.Lancet Oncol · 2016699 citationsRCR 20.7